Patents by Inventor Michael Goldstein

Michael Goldstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tyrosine kinase inhibitors
    Patent number: 8946241
    Abstract: The present disclosure provides compounds such as such as pyrazolpyrimidine compounds, and pharmaceutically acceptable salts thereof, that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: February 3, 2015
    Assignee: Principia Biopharma Inc.
    Inventor: David Michael Goldstein
  • TYROSINE KINASE INHIBITORS
    Publication number: 20140336382
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: July 25, 2014
    Publication date: November 13, 2014
    Applicant: Principia Biopharma Inc.
    Inventor: David Michael GOLDSTEIN
  • KINASE INHIBITORS
    Publication number: 20140323464
    Abstract: Provided herein are kinase inhibiting compounds and methods of using the same.
    Type: Application
    Filed: May 16, 2012
    Publication date: October 30, 2014
    Inventors: John William Taunton, JR., Kenneth Albert Brameld, David Michael Goldstein, Jesse Mcfarland, Shyam Krishnan, Jonathan Choy
  • Method of Submitting Information to a Database Concerning a Stopped Vehicle
    Publication number: 20140317052
    Abstract: A law enforcement officer involved in a traffic stop is provided with a means to submit details of contraband locations within the stopped vehicle to a cloud-based server or database. This method of submitting information allows any other officer to be able to retrieve up-to-date information regarding the location of contraband hidden with a particular vehicle. The data submitted, stored, and accessed from the cloud-based server or database may include methods and instructions for accessing the hiding places, or other relevant information useful for an officer to retrieve contraband.
    Type: Application
    Filed: June 13, 2013
    Publication date: October 23, 2014
    Inventor: Michael Goldstein
  • TYROSINE KINASE INHIBITORS
    Publication number: 20140309223
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: April 17, 2014
    Publication date: October 16, 2014
    Applicant: Principia Biopharma Inc.
    Inventor: David Michael GOLDSTEIN
  • TYROSINE KINASE INHIBITORS
    Publication number: 20140303190
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: February 20, 2014
    Publication date: October 9, 2014
    Applicant: Principia Biopharma Inc.
    Inventor: David Michael GOLDSTEIN
  • Systems and Methods for Message Routing Using Link State Information
    Publication number: 20140244746
    Abstract: Systems and methods for link state-based message routing in messaging systems. An example method, performed by a message broker, may comprise: receiving a topology update message from a second message broker; updating, in view of the topology update message, a data structure storing messaging bus topology information; receiving a message including an identifier of a destination message broker; determining, using the data structure storing messaging bus topology information, an identifier of a peer message broker corresponding to the destination message broker; and forwarding the message to the peer message broker over a messaging bus.
    Type: Application
    Filed: February 26, 2013
    Publication date: August 28, 2014
    Applicant: RED HAT, INC.
    Inventors: Theodore Langston Ross, Andrew Michael Goldstein
  • PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS
    Publication number: 20140221398
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, Jak3, TEC, Btk, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts and processes for preparing such compounds and pharmaceutically acceptable salts.
    Type: Application
    Filed: May 16, 2012
    Publication date: August 7, 2014
    Applicant: Principia Biopharma Inc.
    Inventors: David Michael Goldstein, Kenneth Albert Brameld
  • Tyrosine kinase inhibitors
    Patent number: 8759358
    Abstract: The present disclosure provides compounds such as pyrazolpyrimidine compounds, and pharmaceutically acceptable salts thereof, that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: June 24, 2014
    Assignee: Principia Biopharma Inc.
    Inventor: David Michael Goldstein
  • TYROSINE KINASE INHIBITORS
    Publication number: 20140107151
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, JAK3, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts and processes for preparing such compounds and pharmaceutically acceptable salts.
    Type: Application
    Filed: May 16, 2012
    Publication date: April 17, 2014
    Applicant: Principia Biophama Inc.
    Inventors: David Michael Goldstein, Kenneth Albert Brameld
  • Tyrosine Kinase Inhibitors
    Publication number: 20140094459
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: May 16, 2012
    Publication date: April 3, 2014
    Applicant: Princpia Biopharma Inc.
    Inventors: David Michael Goldstein, Kenneth Albert Brameld
  • Tyrosine kinase inhibitors
    Patent number: 8673925
    Abstract: The present disclosure provides compounds such as pyrazolpyrimidine compounds, and pharmaceutically acceptable salts thereof, that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: March 18, 2014
    Assignee: Principia Biopharma Inc.
    Inventor: David Michael Goldstein
  • AZAINDOLE DERIVATIVES AS TYROSINE KINASE INHIBITORS
    Publication number: 20140073626
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, JAK3, TEC, Btk, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts and processes for preparing such compounds and pharmaceutically acceptable salts.
    Type: Application
    Filed: May 16, 2012
    Publication date: March 13, 2014
    Applicant: Principia Biopharma
    Inventors: David Michael Goldstein, Kenneth Albert Brameld, Erik Verner
  • Inhibitors of JNK
    Patent number: 8642601
    Abstract: Compounds of formula I or pharmaceutically acceptable salts thereof, wherein R5 is a group of formula (a) or (b): and wherein m, n, p, q, X, Y, R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: February 4, 2014
    Assignee: Roche Palo Alto LLC
    Inventors: Humberto Bartolome Arzeno, Lubov K. Filonova, David Michael Goldstein, Leyi Gong, Bradley E. Loe, Erin M. O'Brien, Wylie Solang Palmer, David Mark Rotstein, Tania M. Silva, Yun-Chou Tan
  • TORIC OPHTHALMIC LENS HAVING EXTENDED DEPTH OF FOCUS
    Publication number: 20140022508
    Abstract: An ophthalmic lens is presented. The lens includes a toric optical zone and a phase-affecting, non-diffractive optical element for extending depth of focus of imaging.
    Type: Application
    Filed: December 20, 2011
    Publication date: January 23, 2014
    Applicant: XCEED IMAGING LTD.
    Inventors: Shai Ben-Yaish, Alex Zlotink, Ido Raveh, Ofer Limon, Oren Yehezkel, Karen Lahav-Yacouel, Michael Goldstein, Zeev Zalevsky
  • JNK modulators
    Patent number: 8399462
    Abstract: Compounds of formula I modulate JNK: wherein the variables are as defined herein.
    Type: Grant
    Filed: December 7, 2007
    Date of Patent: March 19, 2013
    Assignee: Roche Palo Alto LLC
    Inventors: James Patrick Dunn, Leyi Gong, David Michael Goldstein, Xiaochun Han, Joan Heather Hogg, Wylie Solang Palmer, Lubica Raptova, Tania Silva, Parcharee Tivitmahaisoon, Teresa Alejandra Trejo-Martin, Christophe Michoud, Achyutharao Sidduri
  • METHOD OF MODELING FOR DRUG DESIGN, EVALUATION AND PRESCRIPTION IN THE TREATMENT OF DISEASE
    Publication number: 20130060537
    Abstract: A method implemented on at least one specifically programmed computer to improve the outcome of a drug trial. The method includes (a) generating a parameterized mathematical model of disease and immune response, (b) including in the parameterized mathematical model effects from one or more drugs with time-dependent variables that can change during a therapy, (c) creating a calibrated model using empirical data to aid in determining parameters of the parameterized mathematical model, (d) determining responses of the calibrated model to a series of time-dependent drug therapies, and (e) selecting at least one therapy based on the determined responses of the model.
    Type: Application
    Filed: September 12, 2011
    Publication date: March 7, 2013
    Inventor: Michael GOLDSTEIN
  • Nitinol Through Tubing Bridge Plug
    Publication number: 20120273199
    Abstract: A bridge plug assembly having a nickel titanium alloy flexible member that can be selectively radially expanded so its outer surface sealingly engages a surrounding tubular. The flexible member can comprise an annular membrane like member having coaxial rings on the opposing ends of the flexible member. The percentage of weight of nickel can range up to about 40 to about 58%, 55% or to about 60%.
    Type: Application
    Filed: April 27, 2010
    Publication date: November 1, 2012
    Applicant: BAKER HUGHES INCORPORATION
    Inventors: Gary Cresswell, Freeman Hill, William Befeld, Gregory Rinberg, Dan Raz, Michael Goldstein
  • Pyrimidinyl pyridone inhibitors of kinases
    Patent number: 8268840
    Abstract: This application discloses novel pyrimidinyl pyridone derivatives according to formula I, wherein A, R1, R2, R3, and m are defined as described herein, which inhibit JNK. The compounds disclosed herein are useful to modulate the activity of JNK and treat diseases associated with excessive JNK activity. The compounds are useful to treat autoimmune, inflammatory, metabolic, and neurological diseases as well as cancer. Also disclosed are compositions comprising the compound of formula I and methods of treatment comprising administering a therapeutically effective amount of the compound of formula I to a subject in need thereof.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: September 18, 2012
    Assignee: Roche Palo Alto LLC
    Inventors: Frederick Brookfield, Florence Eustache, Michael Patrick Dillon, David Michael Goldstein, Leyi Gong, Xiaochun Han, Joan Heather Hogg, Jaehyeon Park, Deborah Carol Reuter, Eric Brian Sjogren
  • Optical device
    Patent number: 8212858
    Abstract: Stereoscopic device including an image directing assembly, an image differentiator and an image detector, the image directing assembly having a first light inlet for receiving a first image and a second light inlet for receiving a second image, the first light inlet being spaced apart from the second light inlet, the image differentiator differentiating between the first image and the second image, wherein the image directing assembly directs the first image to the image detector via a common path, and wherein the image directing assembly directs the second image to the image detector via the common path.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: July 3, 2012
    Assignee: Visionsense Ltd.
    Inventors: Mark Schechterman, Michael Goldstein, Nadav Horesh, Avi Yaron, Martin Abraham